title: Augmentation with buspirone: a review.
abstract: Buspirone, an azaspirone serotonin (5-HT) 1A partial agonist, has been approved by the FDA as an anxiolytic. It has been tested for use in depression, panic disorder, obsessive-compulsive disorder, and schizophrenia as well. Several trials have indicated that it may prove to be a useful agent for augmentation of other psychotropic medications in these disorders. We review the literature supporting the potential use of buspirone as an augmenting agent.
authors.affiliation: Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, Michigan, USA.
authors.forename: K V
authors.initials: KV
authors.lastname: Harvey
authors.forename: R
authors.initials: R
authors.lastname: Balon
mesh_terms: D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D002065:Buspirone / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy; D004347:Drug Interactions; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D016584:Panic Disorder / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*
chemical_list: D014151:Anti-Anxiety Agents; D017366:Serotonin Receptor Agonists; D002065:Buspirone